Hycamtin is a drug owned by Sandoz Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 10, 2024. Details of Hycamtin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8158645 | Compound, corresponding compositions, preparation and/or treatment methods |
Dec, 2024
(12 days ago) |
Expired
|
|
US5674872 (Pediatric) | Treatment of ovarian cancer |
Apr, 2015
(9 years ago) |
Expired
|
| US5674872 | Treatment of ovarian cancer |
Oct, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Hycamtin's patents.
Latest Legal Activities on Hycamtin's Patents
Given below is the list of recent legal activities going on the following patents of Hycamtin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 Oct, 2023 | US8158645 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Oct, 2019 | US8158645 |
| Email Notification Critical | 08 Jun, 2015 | US8158645 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Jun, 2015 | US8158645 |
| Correspondence Address Change Critical | 05 Jun, 2015 | US8158645 |
| Recordation of Patent Grant Mailed Critical | 17 Apr, 2012 | US8158645 |
| Patent Issue Date Used in PTA Calculation Critical | 17 Apr, 2012 | US8158645 |
| Email Notification Critical | 29 Mar, 2012 | US8158645 |
| Issue Notification Mailed Critical | 28 Mar, 2012 | US8158645 |
| Dispatch to FDC | 19 Mar, 2012 | US8158645 |
US patents provide insights into the exclusivity only within the United States, but Hycamtin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Hycamtin's family patents as well as insights into ongoing legal events on those patents.
Hycamtin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Hycamtin's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 10, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Hycamtin Generic API suppliers:
Topotecan Hydrochloride is the generic name for the brand Hycamtin. 11 different companies have already filed for the generic of Hycamtin, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Hycamtin's generic
About Hycamtin
Hycamtin is a drug owned by Sandoz Inc. It is used for treating metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. Hycamtin uses Topotecan Hydrochloride as an active ingredient. Hycamtin was launched by Sandoz in 2007.
Approval Date:
Hycamtin was approved by FDA for market use on 11 October, 2007.
Active Ingredient:
Hycamtin uses Topotecan Hydrochloride as the active ingredient. Check out other Drugs and Companies using Topotecan Hydrochloride ingredient
Treatment:
Hycamtin is used for treating metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy.
Dosage:
Hycamtin is available in the following dosage forms - capsule form for oral use, injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1MG BASE | CAPSULE | Prescription | ORAL |
| EQ 0.25MG BASE | CAPSULE | Prescription | ORAL |
| EQ 4MG BASE/VIAL | INJECTABLE | Prescription | INJECTION |